PMID- 26829656
OWN - NLM
STAT- MEDLINE
DCOM- 20160722
LR  - 20181202
IS  - 1520-6025 (Electronic)
IS  - 0163-3864 (Linking)
VI  - 79
IP  - 2
DP  - 2016 Feb 26
TI  - Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human 
      Glioblastoma Cells.
PG  - 317-23
LID - 10.1021/acs.jnatprod.5b00919 [doi]
AB  - Glioblastoma is one of the most malignant primary tumors, and the prognosis for 
      glioblastoma patients remains poor. Tumor-necrosis-factor-related 
      apoptosis-inducing ligand (TRAIL) is considered a promising anticancer agent due 
      to its remarkable ability to selectively kill tumor cells. However, since many 
      cancers are resistant to TRAIL, strategies to overcome resistance are required 
      for the successful use of TRAIL in the clinic. In the present study, the 
      potential of morusin as a TRAIL sensitizer in human glioblastoma cells was 
      evaluated. Treatment with TRAIL or morusin alone showed weak cytotoxicity in 
      human glioblastoma cells. However, combination treatment of TRAIL with morusin 
      synergistically decreased cell viability and increased apoptosis compared with 
      single treatment. Morusin induced expression of death receptor 5 (DR5), but not 
      DR4 or decoy receptors (DcR1 and DcR2). Furthermore, morusin significantly 
      decreased anti-apoptotic molecules survivin and XIAP. In addition, morusin 
      reduced expression of EGFR and PDFGR as well as phosphorylation of STAT3, 
      possibly mediating down-regulation of survivin and XIAP. Together these results 
      suggest that morusin enhances TRAIL sensitivity in human glioblastoma cells 
      through regulating expression of DR5 and EGFR. Therefore, the combination 
      treatment of TRAIL and morusin may be a new therapeutic strategy for malignant 
      glioma patients.
FAU - Park, Dain
AU  - Park D
FAU - Ha, In Jin
AU  - Ha IJ
AD  - Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine 
      Hospital , Seoul 02447, Republic of Korea.
FAU - Park, Sang-Yoon
AU  - Park SY
FAU - Choi, Minji
AU  - Choi M
FAU - Lim, Sung-Lyul
AU  - Lim SL
FAU - Kim, Sung-Hoon
AU  - Kim SH
FAU - Lee, Jun-Hee
AU  - Lee JH
AD  - Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine 
      Hospital , Seoul 02447, Republic of Korea.
FAU - Ahn, Kwang Seok
AU  - Ahn KS
FAU - Yun, Miyong
AU  - Yun M
AD  - Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine 
      Hospital , Seoul 02447, Republic of Korea.
FAU - Lee, Seok-Geun
AU  - Lee SG
AD  - Korean Medicine Clinical Trial Center, Kyung Hee University Korean Medicine 
      Hospital , Seoul 02447, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160201
PL  - United States
TA  - J Nat Prod
JT  - Journal of natural products
JID - 7906882
RN  - 0 (Flavonoids)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (TNF-Related Apoptosis-Inducing Ligand)
RN  - 62596-29-6 (morusin)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Down-Regulation/drug effects
MH  - ErbB Receptors/*metabolism
MH  - Flavonoids/chemistry/*pharmacology
MH  - Glioblastoma/drug therapy/*genetics/metabolism
MH  - Humans
MH  - Male
MH  - Molecular Structure
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/drug effects/*genetics
MH  - STAT3 Transcription Factor/drug effects
MH  - TNF-Related Apoptosis-Inducing Ligand/metabolism
EDAT- 2016/02/02 06:00
MHDA- 2016/07/23 06:00
CRDT- 2016/02/02 06:00
PHST- 2016/02/02 06:00 [entrez]
PHST- 2016/02/02 06:00 [pubmed]
PHST- 2016/07/23 06:00 [medline]
AID - 10.1021/acs.jnatprod.5b00919 [doi]
PST - ppublish
SO  - J Nat Prod. 2016 Feb 26;79(2):317-23. doi: 10.1021/acs.jnatprod.5b00919. Epub 
      2016 Feb 1.